| Cat.No. | Name | Information |
|---|---|---|
| M6699 | EDTA | EDTA is a chelating agent. EDTA can activate NOTCH1 signaling. |
| M52408 | Jagged-1 (188-204) | Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. |
| M14575 | RBPJ Inhibitor-1 | RBPJ Inhibitor-1 (RIN1) is a first-in-class RBPJ inhibitor that blocks the interaction between RBPJ and SHARP.RBPJ Inhibitor-1 (RIN1) inhibits the proliferation of Notch-dependent tumor cells. |
| M14572 | Jagged-1 (188-204) TFA | Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells. |
| M14569 | Bruceine D | Bruceine D is a Notch inhibitor with anti-cancer activity and induces apoptosis in several human cancer cells. |
| M10798 | BMS-983970 | BMS-983970 is an oral Notch inhibitor with antitumor activity. |
| M10373 | CB-103 | CB-103 is a first-in-class, orally active inhibitor of the Notch transcription activation complex. CB-103 inhibits Notch signaling in primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines, and concomitantly induces cell cycle arrest and apoptosis. |
| M10088 | NVS-ZP7-4 | NVS-ZP7-4 is a potent ZIP7 Inhibitor, which inhibits Notch signaling with IC50 of 0.13 uM in HES-Luc reporter gene assays, selectively induces apoptosis and ER stress. |
| M8679 | IMR-1 | IMR-1 is a first-in-class, cell-permeable inhibitor of the Notch transcription activation complex, with an IC50 of 26 μM. IMR-1 prevents Maml1 from recruiting to the Notch ternary complex (NTC) in chromatin, inhibits transcription of Notch target genes, and has antitumor activity. |
| M4553 | Tangeretin | Tangeretin is a flavonoid from citrus fruit peels, and is also selected as a Notch-1 inhibitor, which plays an important role in anti-inflammatory responses and neuroprotective effects in several disease models. |
| M2828 | LY900009 | LY900009 is a potent, first-in-class Notch inhibitor with IC50 of 0.27 nM. |
| M2703 | FLI-06 | FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM. |
| M52407 | DAPM | DAPM is a Notch pathway inhibitor with anticancer activity and antiproliferative effects. |
| M39205 | Procyanidin B2 3,3'-di-O-gallate | Procyanidin B2, 3,3'-di-O-gallate is an active constituent. Procyanidin B2, 3,3'-di-O-gallate strongly suppresses the constitutive as well as Jagged1 (Notch1 ligand)-induced activated Notch1 pathway. |
| M31064 | SAHM1 TFA | SAHM1 TFA is a Notch pathway inhibitor. SAHM1 TFA stabilizes hydrocarbon-stapled alpha helical peptide. SAHM1 TFA targets the protein-protein interface and prevents Notch complex assembly. |
| M29400 | JI051 | JI051 is a stabilizer for the Hes1-PHB2 interaction. JI051 interacts with a cancer-associated protein chaperone prohibitin 2 (PHB2), induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1. Anti-cancer activity. |
| M29222 | Yhhu-3792 | Yhhu-3792 enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) in mouse. Yhhu-3792 increases the spatial and episodic memory abilities of mice. Yhhu-3792 has the potential for the research of impairment of learning and memory associated DG dysfunction. |
| M29135 | SAHM1 | SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical Notch transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice. |
| M25550 | ASR-490 | ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating Notch1 signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice. |
| M25077 | Tarlatamab | Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
